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Abstract
Selective serotonin (5-HT) reuptake inhibitors (SSRIs) are used as a ﬁrst-line treatment in depression.
However, many depressed patients are also treated with benzodiazepines to alleviate increased anxiety
and sleep disturbances normally associatedwith depression. Since benzodiazepines inhibit 5-HT neuronal
ﬁring activity, they might attenuate SSRI-induced increase in extracellular 5-HT levels. This study aimed
to assess, using in-vivo microdialysis, the eﬀects of the benzodiazepines oxazepam or temazepan on the
SSRI paroxetine-induced 5-HT increase in the hippocampus of freely moving guinea-pigs. It was found
that the acute systemic administration of paroxetine increased extracellular 5-HT levels. Pre-adminis-
tration of oxazepam or temazepam signiﬁcantly diminished the paroxetine-induced elevation of extra-
cellular 5-HT levels (from 350% to 200% of baseline). It was concluded that benzodiazepines attenuate the
ability of SSRIs to elevate hippocampal 5-HT levels. Thus, co-administration of benzodiazepines might
aﬀect the therapeutic eﬃcacy of SSRI treatment.
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First published online 5 January 2010
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Introduction
Selective serotonin (5-HT) reuptake inhibitors (SSRIs)
and benzodiazepines are used as antidepressants and
sedative medications, respectively. SSRIs are currently
considered as a ﬁrst-line treatment in depression
(Kennedy, 2006). Benzodiazepines are given, in ad-
dition to SSRIs to about 35% of depressed patients,
to alleviate increased sleep disturbances, anxiety and
irritation normally associated with depression
(Carvalho et al. 2007; Youssef & Rich, 2008).
The main pharmacological eﬀect of SSRIs is an
increase in extracellular 5-HT levels by selective
blocking of 5-HT transporters (SERT). The increased
extracellular 5-HT level results in the activation of
5-HT1A and 5-HT1B autoreceptors, in turn leading to
suppression of the ﬁring activity of 5-HT neurons.
This suppression of ﬁring activity of 5-HT neurons
challenges the ability of SSRIs to stimulate 5-HT
transmission. After 2–3 wk of SSRI administration,
5-HT1A/1B autoreceptors desensitize and the ﬁring
activity of 5-HT neurons recovers to pre-treatment
levels. This explains, at least in part, the delay between
start of the treatment with SSRIs and the onset of their
clinical eﬀect (Mongeau et al. 1997; Pineyro & Blier,
1999).
It has been previously shown that benzodiazepines
inhibit 5-HT transmission via a c-aminobutyric
(GABA)A receptor-mediated mechanism (Lista et al.
1989, 1990). Since the inhibition of 5-HT neurons at-
tenuates 5-HT release, it is possible that benzodiaz-
epines, co-administered with SSRIs, will challenge
the ability of SSRIs to elevate extracellular 5-HT
levels. The present study aimed to assess, using in-vivo
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microdialysis, the eﬀects of the benzodiazepines
oxazepam or temazepam on the SSRI paroxetine-
induced 5-HT increase in the hippocampus of freely
moving guinea-pigs. Paroxetine was chosen for this
study since it is a widely used and very potent SSRI
(Mertens & Pintens, 1988). Oxazepam and temazepam
represent the newest generation of benzodiazepines.
These fast-acting sedative drugs are widely used be-
cause of their high safety and low side-eﬀects (Breimer
et al. 1980; McElnay et al. 1982).
Methods
Animals
Male albino Dunkin Hartley guinea-pigs (300–400 g;
Harlan, The Netherlands) were used in this study. The
animals were housed in cages (60r40r40 cm) with
food and water available ad libitum. The experiments
were in accord with the Declarations of Helsinki and
were approved by the Institutional Animal Care and
Use Committee of the University of Groningen.
Drugs
Paroxetine hydrobromide (GlaxoSmithKline, UK) was
dissolved in ultrapuriﬁed water and injected sub-
cutaneously (s.c.) at a dose of 5 mg/kg. The paroxetine
dose was chosen based on our previous studies
(Cremers et al. 2001). Oxazepam and temazepam (Bufa
BV, The Netherlands) were dissolved in 10% (v/v)
solutol (a polyoxyethylene ester of 12-hydroxystearic
acid) and ultrapuriﬁed water and administered (s.c.)
at a dose of 0.3 mg/kg each. In the control experiments
where compounds were administered individually,
the appropriate vehicle control for the combination
was co-administered.
Surgery
Animals were pre-medicated with midazolam as
analgesic (5 mg/kg s.c.) and anaesthetized by keta-
mine and xylazine (50 and 8 mg/kg, respectively, i.p.).
Lidocaine-HCl, 10% (w/v) was used for local anaes-
thesia. The animals were placed in a stereotaxic frame
(Kopf, USA), and homemade I-shaped probes (poly-
acrylonitrile/sodium methyl sulphonate co-polymer
dialysis ﬁbre; 4 mm open surface, i.d. 220 mm, o.d.
310 mm, AN69, Hospal, Bologna, Italy) were inserted
into the ventral hippocampus (4.9 mm posterior and
6.5 mm lateral from bregma, 9.0 mm ventral to the
brain surface) and secured with dental cement. Post-
operative analgesia was accomplished by an intra-
muscular injection of 0.1 mg/kg buprenorphine.
Microdialysis
Microdialysis experiments were performed on freely
moving guinea-pigs, as previously described
(Cremers et al. 2001). Brieﬂy, the animals were allowed
to recover for at least 24 h after surgery, before the
probes were perfused with artiﬁcial cerebrospinal
ﬂuid (aCSF; 147 mM NaCl, 3.0 mM KCl, 1.2 mM CaCl2,
1.2 mM MgCl2) delivered at ﬂow rate of 1.5 ml/min
(Harvard apparatus, USA). The samples were col-
lected continuously in 15-min intervals into vials con-
taining 7.5 ml of 20 mM acetic acid.
5-HT assay
Concentrations of 5-HT in microdialysates were
measured by high-performance liquid chromato-
graphy with electrochemical detection, as previously
described (Cremers et al. 2001). Brieﬂy, samples of
20 ml were injected onto a reversed-phase column
(Phenomenex Hypersil 3 :3 mm, 100r2.0 mm, C18;
Bester BV, The Netherlands) by an auto-injector
(CMA/200 refrigerated microsampler, CMA Micro-
dialysis, Sweden). The mobile phase consisted of 5 g/l
di-ammonium sulfate, 500 mg/l ethylenediamino-
tetraacetic acid (EDTA), 50 mg/l heptane sulphonic
acid (pH 4.65) plus 4% methanol (v/v) and 30 ml/l
triethylamine. The mobile phase was delivered at a
ﬂow rate of 0.4 ml/min (Shimadzu LC-10 AD). 5-HT
was detected electrochemically by a glassy carbon
electrode set at a working potential of 500 mV vs. Ag/
AgCl (Antec Leyden, The Netherlands). The detection
limit was 0.5 fmol 5-HT per 20 ml sample (signal-to-
noise ratio: 3).
Data presentation and statistics
Four consecutive microdialysis samples with <20%
variation were taken as baseline and set at 100%. Data
are presented as percentage of baseline level (mean¡
S.E.M.). Statistical analysis was performed using Sigma-
Stat for Windows (SPSS Inc., USA). Treatment eﬀects
were compared vs. saline treatment using two-way
ANOVA for repeated measurements, followed by
Bonferroni’s post-hoc test. Level of signiﬁcance was set
at p<0.05.
Results
The basal levels of 5-HT in the hippocampal dialysates
were 8.87¡0.84 fmol/sample (n=27). Figure 1 shows
the eﬀects of oxazepam and paroxetine on extracellu-
lar 5-HT levels. There were signiﬁcant eﬀects of time
[F(12, 246)=89.59, p<0.001], treatment [F(2, 246)=
60.39, p<0.001], and timertreatment interaction
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[F(24, 246)=29.44, p<0.001]. There was no signiﬁ-
cant change in 5-HT levels in animals administered
oxazepam alone (n=5). In animals administered
paroxetine (n=10) and paroxetine+oxazepam (n=4)
there was a signiﬁcant increase in 5-HT levels com-
pared to baseline (p<0.05 for the time-points 50–
180 min and 65–180 min after paroxetine adminis-
tration). However, the elevation in 5-HT levels
was signiﬁcantly higher in animals administered
paroxetine alone than in animals co-administered
paroxetine+oxazepam (p<0.05 for the time-points
50–180 min after paroxetine administration).
Figure 2 shows the eﬀects of temazepam and
paroxetine on extracellular 5-HT levels. There were
signiﬁcant eﬀects of time [F(12, 233)=49.34, p<0.001],
treatment [F(2, 233)=36.50, p<0.001], and timer
treatment interaction [F(24, 233)=15.79, p<0.001].






































* * * * * * *
Fig. 1. Serotonin (5-HT) levels in hippocampal microdialysate of guinea-pigs administered oxazepam (t=0), paroxetine
(t=30 min) or oxazepam+paroxetine (at t=0 and 30 min, respectively). * p<0.05 compared to baseline, and compared between






































* * * * * * *
Fig. 2. Serotonin (5-HT) levels in hippocampal microdialysate of guinea-pigs administered temazepam (t=0),
paroxetine (t=30 min) or temazepam+paroxetine (at t=0 and 30 min, respectively). * p<0.05 compared to baseline,
and compared between paroxetine- and paroxetine+oxazepam-treated animals (Bonferroni’s post-hoc test).
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animals administered temazepam alone (n=4). In
animals administered paroxetine (n=10) and parox-
etine+temazepam (n=4) there was a signiﬁcant
increase in 5-HT levels compared to baseline (p<0.05
for the time-points 65–180 min after paroxetine ad-
ministration). However, the elevation in 5-HT levels
was signiﬁcantly higher in animals administered
paroxetine alone than in animals co-administered
paroxetine+temazepam (p<0.05, for the time-points
65–180 min after paroxetine administration).
Discussion
The present study aimed to assess, using in-vivo
microdialysis, the eﬀects of oxazepam or temazepam
on the SSRI paroxetine-induced 5-HT increase in the
hippocampus of freely moving guinea-pigs. It was
found that paroxetine increased extracellular 5-HT
levels. Oxazepam and temazepam, administered in-
dividually, did not alter hippocampal 5-HT levels.
However, when these drugs were co-administered
with paroxetine, they attenuated paroxetine-induced
hippocampal 5-HT release. No statistical diﬀerence
was observed between oxazepam and temazepam in
their ability to diminish paroxetine-induced increase
in hippocampal 5-HT levels.
The present study demonstrated that the SSRI
paroxetine, given alone, results in a 350% increase in
extracellular 5-HT levels in the guinea-pig hippo-
campus. This is probably due to inhibition of 5-HT
reuptake by paroxetine. The paroxetine-induced in-
crease in extracellular 5-HT, observed in the present
study, is in agreement with previous studies using
paroxetine and other SSRIs (Cremers et al. 2001;
Dremencov et al. 2003). The paroxetine dose used was
chosen based on a previous pharmacokinetic study
with this drug (Cremers et al. 2001). In that study
subcutaneous administration of 5 mg/kg paroxetine
resulted in the steady-state presence of that drug in
guinea-pig plasma, where lower doses failed to create
a steady-state plasma concentration.
The present study demonstrated that oxazepam or
temazepam, given alone, did not alter extracellular
5-HT levels in the guinea-pig brain. However, Pei
et al. (1989) reported that benzodiazepines decrease
extracellular 5-HT in the rat hippocampus. The diﬀer-
ence between these ﬁndings might be caused by the
diﬀerent treatments used in the two studies. Here,
oxazepam and temazepam were administered in low
doses (0.3 mg/kg), whereas the study by Pei et al.
(1989) was performed with ﬂurazepam and diazepam
administered at relatively high doses of 10 mg/kg
each.
The main ﬁnding of the present study is the potency
of benzodiazepines. When given in small doses they
do not aﬀect 5-HT transmission, but do attenuate
SSRI-induced elevation in brain 5-HT levels. It is
unlikely that the eﬀects of oxazepam and temazepam
on paroxetine-induced elevation of 5-HT levels are
explained by pharmacokinetic interaction between
these drugs: metabolism of paroxetine is mediated via
2D6, and metabolism of benzodiazepines via the sub-
type 3A4 of the enzyme cytochrome P450 (Nemeroﬀ
et al. 1996; Gregor et al. 1997).
It is possible that oxazepam and temazepam atten-
uate paroxetine-induced increase in 5-HT levels by
suppressing the ﬁring activity of 5-HT neurons. It was
reported that the benzodiazepine diazepam, adminis-
tered alone, does not aﬀect the ﬁring activity of 5-HT
neurons in the rat dorsal raphe nucleus (DRN).
However, pretreatment with 1 mg/kg diazepam
potentiated the inhibitory eﬀect of local GABA ad-
ministration on the ﬁring activity of 5-HT neurons
in the DRN (Gallager, 1978). Another study demon-
strated that the administration of 0.1 mg/kg diazepam
reversed the inhibition of hippocampal neurons in-
duced by the electrical stimulation of 5-HT pathways
(Lista et al. 1989, 1990). This benzodiazepine-induced
potentiation of GABA-mediated inhibition of 5-HT
neurons might explain the oxazepam- and temaze-
pam-induced attenuation of paroxetine-induced 5-HT
release. On the other hand, this lack of a direct sup-
pressive eﬀect of benzodiazepines on the ﬁring of
5-HT neurons possibly explains why oxazepam and
temazepam do not totally reverse paroxetine-induced
5-HT release.
Since the ability to increase extracellular 5-HT levels
suggests modulation of the clinical potency of SSRIs
(Moore et al. 2005; Yevtushenko et al. 2007), co-
administration of benzodiazepines to SSRI-managed
patients may aﬀect the therapeutic eﬃcacy of the
treatment. As many depressed patients receive
benzodiazepines (Youssef & Rich, 2008), the dose of
antidepressant should be carefully adjusted. In ad-
dition, inclusion of benzodiazepine-managed subjects
into clinical trials with antidepressant drugs should
be carefully considered (Bordet et al. 1998).
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